Arcus Biosciences (RCUS) Current Assets (2017 - 2026)

Arcus Biosciences' Current Assets history runs 10 years deep, the most recent figure standing at $844.0 million for Q1 2026.

• On a quarterly basis, Current Assets fell 18.14% year-over-year to $844.0 million in Q1 2026; TTM through Mar 2026 was $844.0 million, a 18.14% decrease from a year earlier, with the FY2025 full-year figure at $1.0 billion, down 0.89% from the prior year.
• Current Assets fell to $844.0 million in Q1 2026 per RCUS's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Current Assets topped out at $1.3 billion in Q1 2022 and bottomed at $831.0 million in Q4 2023.
• The 5-year median for Current Assets is $1.0 billion (2024), against an average of $1.0 billion.
• Across the five-year window, Current Assets jumped 101.93% in 2022 and decreased 23.96% in 2025, its largest moves.
• Year by year, Current Assets stood at $1.1 billion in 2022, then decreased by 22.12% to $831.0 million in 2023, then grew by 22.26% to $1.0 billion in 2024, then retreated by 0.89% to $1.0 billion in 2025, then declined by 16.19% to $844.0 million in 2026.
• Per Business Quant, the three latest RCUS Current Assets figures stand at $844.0 million (Q1 2026), $1.0 billion (Q4 2025), and $857.0 million (Q3 2025).